Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $59
Portfolio Pulse from jenniferd'souza@benzinga.com
Barclays analyst Matt Miksic maintains an Overweight rating on Boston Scientific (NYSE:BSX) and raises the price target from $56 to $59.
July 31, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Boston Scientific and raises the price target from $56 to $59, which could lead to a positive impact on the stock.
The raised price target by Barclays indicates a positive outlook for Boston Scientific. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100